

Fig. 1

InterMune, Inc.

Protocol GIPF-901: Subcutaneous IFN- γ for Idiopathic Pulmonary Fibrosis

Table 19.3.3

Cumulative Probability of Survival^a - Kaplan-Meier Estimates (Standard Errors)
 Baseline FVC \geq Predicted: < 55
 Intent-to-Treat

Week	IFN- γ 1b (N = 36)	Placebo (N = 40)	P-value ^a
Week 12	0.92 (0.046)	0.95 (0.025)	
Week 24	0.89 (0.052)	0.90 (0.047)	
Week 36	0.83 (0.062)	0.88 (0.052)	
Week 48	0.75 (0.073)	0.82 (0.061)	
Week 60	0.75 (0.073)	0.82 (0.061)	
Week 72	0.68 (0.090)	0.82 (0.061)	
Week 84	0.68 (0.090)	0.82 (0.061)	0.434

Time to Survival (Days)†
 75th Percentile 318.0

Number (%) of Survivors 26 (72.2%) 33 (82.5%)

^a Distribution of time to the occurrence of death.

† Time to Survival (Days) = Date of death - Date of randomization + 1.

For patients who survive as of 6/26/2002 the time to survival was considered a censored observation.

Days = June 26 2002 - Date of randomization + 1.

* Test for treatment effect using log rank test stratified by smoking status.

Fig. 2

Intersune, Inc.
Protocol GIPP-001: Subcutaneous IFN- γ for Idiopathic Pulmonary Fibrosis

Table 19.3.5

Cumulative Probability of Survival* - Kaplan-Meier Estimates (Standard Errors)
Baseline FVC \geq Predicted: ≥ 55
Intent-to-Treat

Week	IFN- γ lb (N = 126)	Placebo (N = 129)	P-Value*
Week 12	1.00 (0.000)	0.99 (0.008)	
Week 24	0.98 (0.011)	0.98 (0.011)	
Week 36	0.98 (0.011)	0.94 (0.021)	
Week 48	0.98 (0.014)	0.90 (0.026)	
Week 60	0.94 (0.027)	0.85 (0.034)	
Week 72	0.94 (0.027)	0.80 (0.047)	
Week 84	0.94 (0.027)	0.68 (0.090)	0.004

Time to Survival (Days)†
75th Percentile

518.0

Number (%) of Survivors

120 (95.2%) 107 (83.6%)

* Distribution of time to the occurrence of death.

† Time to Survival (Days) = Date of Death - Date of randomization +1.

For patients who survive as of 6/26/2002 the time to survival was considered a censored observation.

Days = June 26 2002 - Date of randomization +1.

* Test for treatment effect using log rank test stratified by smoking status.